Key facts
- This page summarizes James E. Francese's Form 4 filing for STAAR SURGICAL CO (STAA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Mar 2022, 17:44.
James E. Francese - 07 Mar 2022 Form 4 Insider Report for STAAR SURGICAL CO (STAA)
- Reporting relationship
- Sr. VP, Comm. Ops., NA, APAC
- Issuer ticker
- STAA
- Reported as of
- 07 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Mar 2022, 17:44:18 UTC
- Prior SEC filing
- 18 Aug 2021
- Next SEC filing
- 16 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Samuel Gesten as attorney-in-fact for James Francese
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James E. Francese filed Form 4 for STAAR SURGICAL CO (STAA) on 08 Mar 2022.
Change
- Previous filing in this sequence was filed on 18 Aug 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
STAA
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +5,839
- Change %
- +11%
- Price
- $0.000000
- Shares after
- 58,469
- Date
- 07 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
STAA
transaction
Derivative
Common Stock Options
Options Exercise
- Transaction value
- $0
- Shares
- +12,146
- Change %
- Price
- $0.000000
- Shares after
- 12,146
- Date
- 07 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,146
- Exercise price
- $74.80
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Award of 5839 Restricted Stock Units of Common Stock (RSU), subject to forfeiture rights, which lapse as to 1/3 of the RSUs on 3/7/23, 1/3 of the RSUs on 3/7/24, and the remaining 1/3 of the RSUs on 3/7/25.
Footnote F2
The options granted become exercisable as follows: 1/3 on 3/7/2023 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/7/2025.